Autoimmune heparin‐induced thrombocytopenia (aHIT) indicates the presence in patients of
anti‐platelet factor 4 (PF4)–polyanion antibodies that are able to activate platelets strongly …

Heparin-induced thrombocytopenia (HIT) is an immune complication of heparin therapy
caused by antibodies to complexes of platelet factor 4 (PF4) and heparin. Pathogenic …

Abstract SARS-CoV-2 vaccine ChAdOx1 nCoV-19 (AstraZeneca) causes a thromboembolic
complication termed vaccine-induced immune thrombotic thrombocytopenia (VITT). Using …

Heparin has been recognized as a valuable anticoagulant and antithrombotic for several
decades and is still widely used in clinical practice for a variety of indications. The …

Heparin-induced thrombocytopenia (HIT) is characterized clinically by thrombocytopenia,
hypercoagulability, and increased thrombosis risk, and serologically by platelet-activating …

Many antisense oligonucleotides (ASOs) from several classes of molecules are currently in
drug development. Despite over 20 years of pharmaceutical research, few ASOs have been …

Drug-induced immune thrombocytopenia (DITP) is a life-threatening clinical syndrome that
is under-recognized and difficult to diagnose. Many drugs can cause immune-mediated …

As of 4 April 2021, a total of 169 cases of cerebral venous sinus thrombosis (CVST) and 53
cases of splanchnic vein thrombosis were reported to EudraVigilance among around 34 …

Abstract Platelet factor 4 (PF4) is a highly cationic tetrameric protein that can be targeted by
platelet-activating anti-PF4 antibodies of immunoglobulin G (IgG) class. Certain features of …

A clinically important adverse drug reaction, heparin-induced thrombocytopenia (HIT), is
induced by antibodies specific for complexes of the chemokine platelet factor 4 (PF4) and …